CKD273尿液蛋白质组生物标志物预测慢性肾脏病3期
本研究纳入6个队列2087例基线eGFR≥60 ml/min/1.73 m2的个体,评估尿液生物标志物CKD273预测eGFR降至<60 ml/min/1.73 m2的能力。结果显示CKD273与UAE均能预测首次和持续性肾脏终点,且CKD273在连续变量分析中改善IDI而UAE未改善。结论认为在校正基线eGFR、白蛋白尿及协变量后,CKD273可增加对3期CKD的预测。
要点
- CKD273与UAE均预测eGFR降至<60 ml/min/1.73 m2的首次和持续性终点。
- CKD273作为连续标志物改善IDI(P=0.039),UAE未改善(P=0.065)。
- CKD273阈值≥0.154时敏感度33%、特异度83%。
核心结论
- 在校正基线eGFR、白蛋白尿及协变量后,CKD273可增加对3期慢性肾脏病的预测。
研究设计与样本
- 研究分析了来自6个队列的2087例个体,其中女性46.4%,糖尿病73.5%,平均年龄46.1岁,基线eGFR≥60 ml/min/1.73 m2者占100%,UAE≥20 μg/min者占6.2%。
- 分析中校正了队列、性别、年龄、平均动脉压、糖尿病和基线eGFR,并按尿液生物标志物每1个标准差增量表达关联。
主要发现
- 中位随访5次访视期间,基线CKD273较高者eGFR下降幅度大于UAE较高者(1.64 vs. 0.82 ml/min/1.73 m2;P < 0.0001)。
- 中位4.6年随访期间,390例发生首次肾脏终点(eGFR下降≥10且<60 ml/min/1.73 m2),172例发生随访期间持续存在的终点。
- 首次和持续肾脏终点风险随UAE(风险比≥1.23;P ≤ 0.043)和CKD273(≥1.20;P ≤ 0.031)升高而增加。
- UAE≥20 μg/min和CKD273≥0.154阈值的敏感度分别为30%和33%,特异度分别为82%和83%(两者正确分类个体比例的差异P ≤ 0.0001)。
- 作为连续标志物,CKD273改善IDI(P = 0.039),UAE未改善(P = 0.065);两者均改善NRI(P ≤ 0.0003),但UAE按阈值分析未改善(P = 0.086)。
关键数值与推荐
- CKD273阈值≥0.154时,敏感度33%,特异度83%。
- UAE阈值≥20 μg/min时,敏感度30%,特异度82%。
临床怎么用
- CKD273可作为预测eGFR降至<60 ml/min/1.73 m2的尿液生物标志物,辅助识别3期CKD高风险个体。
- 在基线eGFR、白蛋白尿及协变量基础上,CKD273可额外提供预测信息,支持早期干预目标的设定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to <60 ml/min per 1.73 m2. METHODS: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR ≥ 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] ≥20 μg/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers. RESULTS: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m2; P < 0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by ≥10 to <60 ml/min per 1.73 m2), and 172 experienced an endpoint sustained over follow-up. The risk of a first and sustained renal endpoint increased with UAE (hazard ratio ≥ 1.23; P ≤ 0.043) and CKD273 (≥ 1.20; P ≤ 0.031). UAE (≥20 μg/min) and CKD273 (≥0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P ≤ 0.0001 for difference between UAE and CKD273 in proportion of correctly classified individuals). As continuous markers, CKD273 (P = 0.039), but not UAE (P = 0.065), increased the integrated discrimination improvement, while both UAE and CKD273 improved the net reclassification index (P ≤ 0.0003), except for UAE per threshold (P = 0.086). DISCUSSION: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.
引用
- Pontillo C, Zhang ZY, Schanstra JP, et al. Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney Int Rep. 2017. PMID: 29130072. doi:10.1016/j.ekir.2017.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。